Names | |
---|---|
Preferred IUPAC name
2-{3,5-Dimethoxy-4-[(2-methylprop-2-en-1-yl)oxy]phenyl}ethan-1-amine | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C14H21NO3 | |
Molar mass | 251.326 g·mol−1 |
Pharmacology | |
Legal status | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
4-methylallyloxy-3,5-dimethoxyphenethylamine (more commonly known as methallylescaline, and abbreviated as MAL) is a lesser-known psychedelic drug. It is the 4-methyl analog of allylescaline. MAL was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage range is listed as 40–65 mg, and the duration is listed as 12–16 hours.[2] Little data exists about the pharmacological properties, metabolism, and toxicity of MAL. The effects of MAL are comparable to that of other mescaline analogs, although with a longer duration. MAL has been sold as a designer drug.[3][4] At very high doses (30 mg/kg) MAL, as well as the psychedelic amphetamine DOI, causes neuroinflammation and loss of serotonergic neurons in mice.[5]